Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recaticimab for symptomatic intracranial atherosclerotic stenosis
NCT07119918Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of recaticimab in Intracranial atherosclerotic stenosis (ICAS), sponsored by Sun Yat-sen Memorial Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
recaticimab
03
Conditions
Intracranial atherosclerotic stenosis (ICAS)
Beyond the preview
Go deeper on NCT07119918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07119918.